22 September 2023
22 September 2023
Although pain affects millions of people worldwide, the industry is still struggling in the ongoing search for safe and effective medication.
The Department of Defense grant is to study methylone for the rapid and long-lasting treatment of PTSD.
Medicenna is also starting to enrol patients in an ongoing Phase I/II trial in solid tumours investigating dose expansion of MDNA11.
The company plans to commence a Phase IIa study in MDD patients in the second half of this year.
Reductions of 24 and 27-hydroxycholesterol levels in the cerebrospinal fluid were observed.
The UK-based surgical robotics company has now raised over $1bn in funding, cementing its unicorn status.
The study is enrolling patients with Duchenne muscular dystrophy who are exon 44 skipping amenable.
The company expects to release topline data from the trial by the end of this year.
The Excellence Awards celebrate the greatest achievements and innovations in the industry, and the people and companies that are driving change.
The success of CAR-Ts in MM has fueled R&D investment into this class of therapy, with more CAR-Ts in development than all other cell and gene therapy classes combined. The approval of the autologous CAR-T cell therapies Abecma and Carvykti sees the CAR-T pipeline mostly constituted of autologous drugs. However, there are also multiple allogeneic CAR-Ts in the pipeline, with these therapies having an “off-the-shelf” advantage over autologous therapies.
Give your business an edge with our leading industry insights.
